ZIOPHARM Oncology (ZIOP) Trading -8.7% Higher

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) rose 8.7% on Thursday . The stock traded as high as $4.50 and last traded at $4.09. Approximately 1,354,670 shares traded hands during trading, a decline of 30% from the average daily volume of 1,938,481 shares. The stock had previously closed at $4.48.

ZIOP has been the subject of several analyst reports. Zacks Investment Research raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Saturday, January 6th. HC Wainwright set a $10.00 price target on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a research report on Thursday, December 14th. Raymond James Financial reissued a “hold” rating on shares of ZIOPHARM Oncology in a research report on Monday, December 11th. BidaskClub raised shares of ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. Finally, ValuEngine downgraded shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $7.50.

How to Become a New Pot Stock Millionaire

The stock has a market cap of $649.02, a PE ratio of -8.04 and a beta of 1.42.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.59 million. ZIOPHARM Oncology’s revenue was up .0% on a year-over-year basis. During the same period last year, the business earned ($0.11) EPS. sell-side analysts expect that ZIOPHARM Oncology Inc. will post -0.58 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its position in shares of ZIOPHARM Oncology by 3.4% during the fourth quarter. BlackRock Inc. now owns 8,499,209 shares of the biotechnology company’s stock valued at $35,187,000 after acquiring an additional 280,003 shares in the last quarter. State Street Corp grew its position in ZIOPHARM Oncology by 12.8% in the 2nd quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock worth $28,342,000 after purchasing an additional 517,057 shares during the period. Geode Capital Management LLC grew its position in ZIOPHARM Oncology by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 1,160,653 shares of the biotechnology company’s stock worth $4,805,000 after purchasing an additional 22,575 shares during the period. Schwab Charles Investment Management Inc. grew its position in ZIOPHARM Oncology by 4.2% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 644,642 shares of the biotechnology company’s stock worth $2,669,000 after purchasing an additional 26,053 shares during the period. Finally, Deutsche Bank AG grew its position in ZIOPHARM Oncology by 141.1% in the 4th quarter. Deutsche Bank AG now owns 294,287 shares of the biotechnology company’s stock worth $1,216,000 after purchasing an additional 172,227 shares during the period. 39.74% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2018/03/10/ziopharm-oncology-ziop-trading-8-7-higher.html.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply